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The gastro-intestinal tract is an extensive organ involved in several activities, with a
crucial role in immunity. Billions of commensal and transient microorganisms, known as
the gut microbiota, and potential pathogens, which are constantly stimulating intestinal
immunity, colonize the intestinal epithelial surface. The gut microbiota may be regarded
as analogous to a solid organ with multiple different functions. In the last decade,
many studies have demonstrated that intestinal bacteria can be a decisive factor in the
health-disease balance of the intestine, and they can also be responsible for illnesses
in other locations. For this reason, fecal microbiota transplantation (FMT) represents
an important therapeutic option for Clostridium difficile infections and hold promise
for different clinical conditions, such as multiple sclerosis, autism, obesity, and other
systemic diseases. FMT consists of the infusion of a fecal suspension from a healthy
donor to a recipient in order to restore gut flora alterations. Similar to the gut, the female
reproductive tract is an example of a very complex biological ecosystem. Recent studies
indicate a possible relationship between the gut and female tract microbiota, associating
specific intestinal bacteria patterns with genital female diseases, such as polycystic ovary
syndrome (PCOS), endometriosis and bacterial vaginosis (BV). FMT could represent a
potential innovative treatment option in this field.
Keywords: cervical-vaginal microbiota, uterine microbiota, gut micobiota, fecal microbiota transplant (FMT),
probiotics, immunmodulation, next generation sequencing (NGS)
INTRODUCTION
The gut microbiota, which is composed of 1013-1014 bacterial cells (1), has multiple different
functions. In the last decade, studies have shown that intestinal bacteria can interact with other
organs and be a decisive factor in health/disease balance beyond just the intestine (2). The gut and
vaginal microbiota are examples of very complex biological ecosystems. The female reproductive
tract has developed unique structures, such as the vagina and uterus. While the vagina hosts
trillions of bacteria, the upper reproductive tract remains largely unexplored and has generally
been considered sterile. The vaginal microbiota interacts with the immune system. Despite being
one of the simplest commensal bacterial communities in the human body, we are only beginning
to appreciate its complex dynamic nature and modulation of host immunity (3). Toll-like receptor
(TLR)-mediated signaling, for example, regulates mucin secretions, contributing to local bacteria
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colonization (4). The relationship between the gut and female
reproductive tract microbiota has been studied in-depth (5).
Driving microbial colonization in the gut could be a very
interesting approach for the treatment of many diseases. Fecal
microbiota transplantation (FMT) is an important therapeutic
option for Clostridium difficile [or Clostridioides difficile-
like, as reported by Oren et al. (6)] infections (CDI) (7).
Promising findings suggest that FMT may also play a role in
the management of genital female disorders associated with
microbiota alterations.
HUMAN GUT MICROBIOTA
Human microbiota is composed of archea, bacteria, yeasts,
fungi, viruses, and protists (8), whose composition has not been
completely described also because there is a substantial inter-
individual. Human gut microbiota is a complex ecosystem with
several functions integrated into the host organism, interacting
with metabolic, immune, and nutrient absorption activities. The
gastrointestinal tract harbors ∼1013-1014 bacterial cells (1, 9),
consisting of strict anaerobes that outnumber the facultative
anaerobes and aerobes by a factor of two to three; these
include Firmicutes, Bacteroidetes, and Proteobacteria, while
Actinobacteria contribute less to the total bacterial composition.
Bacteroidetes include the genera Prevotella and Bacteroides;
the phylum Actinobacteria includes Bifidobacterium; and the
phylum Firmicutes includes Clostridium clusters and members
of Eubacterium, Faecalibacterium, Roseburia, and Ruminococcus
(10). The presence of many different bacterial species is crucial
for defining the role of gut microbiota in various metabolic
pathways. Gut microbiota is a dynamic system that changes and
evolves during our lifetime according to anatomical, dietary,
environmental, pathological, and pharmacological factors (e.g.,
the use of antibiotics, probiotics) (11). This variability in
terms of bacterial species is distributed throughout the various
districts of the gastrointestinal system. Starting from the upper
gastro-intestinal tract, the throat and distal esophagus, the
predominant genera are Streptococcus, Prevotella, Actinomyces,
Gemella, Rothia, Granulicatella, Haemophilus, and Veillonella
(12). In the stomach, microbial diversity depends upon the
presence and absence of Helicobacter pylori (13, 14). A stomach
lacking H. pylori is mainly populated by Streptococcus spp.,
Actinomyces spp., Prevotella spp., and Gemella spp., which are
predominantly found in the throat, indicating that they may
be transient residents coming from the throat (12). The recto-
sigmoid colon microbiota is more complex than the jejunum,
ileum, and caecum resident microbes. Enterococci, E. coli,
Klebsiella, Lactobacilli, Staphylococci, and Streptococci are present
in the jejunum and ileum. Most of the microbes of the jejunum
and ileum are aerobes and facultative anaerobes (15). The small
intestine harbors the aerobic Enterococcus group, Lactobacilli,
Streptococci, and Gammaproteobacteria, while anaerobes are
predominant in the large intestine. Caecal microbiota is more
complex than jejunal and ileal microbiota. The caecal bacteria
are predominated by Lactobacillus, Enterococcus, and Escherichia
coli (16). In the recto-sigmoidal colon, strict anaerobic bacteria
belonging to Bacteroides, Clostridium coccoides, and Clostridium
leptum are the predominant bacterial groups (15). Given the
complexity and multifactorial in terms of the evolution of
the human intestinal microbiota, it is difficult to establish the
composition of an ideal and healthymicrobiota. Generally, a state
of eubiosis is characterized by a strong presence of Firmicutes and
Bacteroidetes and by a low percentage of Proteobacteria, which,
instead, increase during inflammatory states (17). Another aspect
that should be underlined is crosstalk between the gut microbiota
and immune system. This point is extensive and critical. It allows
for the tolerance of commensal bacteria and oral food antigens
and also enables the immune system to recognize and attack
opportunistic bacteria in order to prevent invasion and infection.
In addition, microbiota has broader effects contributing to
innate and adaptive immunity at multiple levels. This concept
is supported in preclinical models, as germ-free mice lacking
intestinal microbiota are subject to severe immunity defects, with
a marked reduction of mucous layer, altered IgA secretion and
reduced size and functionality of Peyer’s patches and draining
mesenteric lymph nodes (1).
FECAL MICROBIOTA TRANSPLANTATION
Given the fundamental role played by the human microbiota in
the health/disease balance, the integrity of this system turns out
to be an important therapeutic target (18). The most innovative
therapeutic approach is represented by FMT. In the last decade,
FMT has been an example of a valid solution, with success of
∼90%, resulting in a more effective regimen for Clostridium
difficile infection (CDI) than vancomycin (19). FMT consists of
the infusion of a feces suspension from a healthy donor to the
intestinal tract of a recipient patient in order to treat a specific
disorder associated with alteration of gut microbiota (7, 20). In
the European Consensus Conference (7), 28 experts from 10
countries collaborated to establish practice guidelines about FMT
indications, donor selection, preparation of fecal suspension,
clinical management, and basic requirements for implementing
an FMT center. An aspect to highlight in FMT assessment
is the healthy donor selection. First, potential donors have to
undergo a medical interview to exclude risk factors. The main
objective of donor selection is to reduce and prevent any adverse
events related to the infused fecal material (21). Subsequently,
serological and microbiological exams are performed on donor’s
fresh stool and blood. The aim is to avoid any possible
infection. Laboratorists check for the presence of any pathogens,
such as HIV, HBV, HCV, Treponema pallidum, Human T-
lymphotropic virus I and II, Plasmodium spp., Trypanosoma spp.,
Mycobacterium tuberculosis, Campylobacter spp., Escherichia coli
O157 H7, Yersinia, vancomycin-resistant enterococci (VRE),
methicillin-resistant Staphylococcus aureus (MRSA), Gram-
negative multidrug-resistant bacteria,Norovirus, antigens and/or
acid fast staining for Giardia lamblia and Cryptosporidium
parvum, protozoa (including Blastocystis hominis), helminths,
and fecal occult blood testing. Regarding the laboratory
preparationmethod, it is possible to choose between two different
procedures: fresh and frozen preparations (22, 23). The first
procedure requires that the feces of the donor be processed within
6 h after defecation to preserve the integrity of the anaerobic
bacteria (24). Any amount of feces ranging from 30 to 50 g
should be used and diluted in saline solution (NaCl 0.9%). The
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frozen approach consists of freezing fecal suspensions with the
addition of glycerol at −80◦C. Glycerol is necessary to preserve
bacterial vitality during freezing (7). On the day of infusion,
fecal suspension thawing should be performed at 37◦C and
then diluted to the desired volume by adding NaCl 0.9% (7,
25). Freezing feces is important for establishing a stool bank
and the availability of stool on demand. Both methods have
high efficacy (7). Promising findings suggest that FMT can also
be used in the management of other extra-intestinal disorders
associated with microbiota alterations. Some clinical conditions
in which FMT could be a potential therapeutic method are
described in Figure 1.
GENITAL FEMALE MICROBIOTA
THROUGHOUT LIFE
The vaginal district is a complex and essential ecosystem
for female health and conception achievement/success. One
aspect that needs to be observed is the microbial population
residing in this region (34). In the last decade, metagenomic
analysis has allowed researchers to outline the vaginal microbial
ecosystem. The predominant species detected in the vagina of
most healthy women are Lactobacillus crispatus, Lactobacillus
gasseri, Lactobacillus iners, and Lactobacillus jensenii (35).
Other important microbes found in healthy women are
strictly anaerobic bacteria, such as Atopobium, Gardnerella
(an opportunistic pathogen), Megasphaera, Prevotella, and
Peptoniphilus (36). One important aspect is the dynamic shift
that occurs across the female lifecycle and how it contributes to
maintaining vaginal health. During perinatal development, the
vaginal epithelium is thickened by residual maternal estrogen.
This action allows for the deposition of glycogen in epithelial
cells. Subsequently, glycogen is released by exfoliation of the
epithelial cells, favoring glucose-fermenting microorganisms
(37). Postnatally, when maternal estrogen is metabolized,
the vaginal mucosa undergoes a thinning that leads to a
reduction in glycogen and glucose-fermenting microorganisms
and an ecological selection for a wide range of aerobes and
facultative anaerobes (35). During childhood, microbiota
is mostly populated by Gram-negative anaerobes, such as
Bacteroides, Fusobacterium, Veillonella, and some Gram-
positive anaerobes, including Actinomyces, Bifidobacterium,
Peptococcus, Peptostreptococcus, and Propionibacterium.
FIGURE 1 | Potential use of FMT in systemic clinical disorders. These diseases are hypothesized being associated to specific gut bacteria alterations (26–33).
Frontiers in Immunology | www.frontiersin.org 3 November 2019 | Volume 10 | Article 2653
Quaranta et al. FMT and Female Reproductive Tract
Regarding facultative anaerobic bacteria, Staphylococcus
aureus, Staphylococccus epidermidis, Streptococcus viridans, and
Enterococcus faecalis are mostly found (38). In prepubertal
age, Lactobacillus, Gardnerella vaginalis, and Prevotella bivia
are in low abundance. As described above, estrogen levels play
a key role in vaginal bacteria colonization. Specifically, with
the beginning of puberty, estrogen increases lead to further
thickening, selecting for glucose-fermenting microorganisms.
During adolescence, the microbiota evolves and becomes similar
to the vaginal microbiota of adult women. In this stage, the
dominant species are Lactobacillus crispatus, Lactobacillus
gasseri, Lactobacillus iners, and Lactobacillus jensenii (38). The
great decline of estrogen levels during menopause leads to a
further switch in vaginal bacterial composition. In this stage
of life, the microbiome is mainly characterized by L. crispatus,
L. iners, G. vaginalis, and Prevotella and a lower abundance
of Mobiluncus, Staphylococcus, Bifidobacterium, Gemella, and
yeasts, such as Candida (39).
UTERINE AND CERVICOVAGINAL
MICROBIOTA AND LOCAL FACTORS
The uterus and vagina are in close anatomical proximity. For
this reason, it is necessary to consider their microbial community
as in continuous cross-talk. Cervicovaginal microbiota consists
of 108 bacteria/gram of vaginal fluid (40); it is decisive in
women’s health and reproductive outcomes. Despite being
one of the simplest commensal bacterial communities in the
human body, we are only beginning to appreciate its complex
dynamic nature and important role in host immune modulation.
Bacteria in the urogenital tract represent 9% of the total human
microbiota, and most of them are difficult to culture. For
almost a century, a common opinion stated that a healthy
uterine cavity was germ-free (41). It was hypothesized that this
sterility is guaranteed by the cervical plug, which constitutes an
impermeable barrier to any bacteria coming from the vagina
(42). In the last decade, many studies have challenged this
assumption using culture-dependent methods and investigating
the composition of the cervical mucous plug, which has been
shown to not be impermeable to bacterial migration from
the vaginal tract (35). In this review, our main question was
whether to consider these microbes as “residents,” “tourists,”
or “invaders.” The uterus and vagina are in strict continuity,
allowing for an inevitable flow of bacteria to the uterine cavity
and a dysregulation of uterine contractions, which may also
promote bacterial colonization. Lactobacilli are fundamental for
female reproductive tract homeostasis. The principal feature
that makes lactobacilli defenders of the cervicovaginal niche is
represented by their production of lactic acid and hydrogen
peroxide, whichmaintain an acidic environment, with a pH∼4.0,
which is inhospitable to the growth of catalase-negative bacteria.
Ravel et al. (36), studied the cervicovaginal ecosystem among
North American women of reproductive age using bacterial 16S
rRNA gene sequencing. The results suggested the presence of five
community state types (CSTs). CSTs I-IV are characterized by an
abundance of Lactobacillus species (CST I, L. crispatus; CST II, L.
gasseri; CST III, L. iners; CST V, L. jensenii), while CTS V consists
mainly of anaerobes (36). Lactobacillus-dominant communities
have shown important prevalence differences among healthy
woman depending on their racial belonging. In fact, Lactobacillus
spp. ranged from 90% in white women, 80% in Asian women and
only 60% in Hispanic and black women. Moreover, it has been
demonstrated that specific cervicovaginal bacteria are related to
HIV acquisition. Specifically, in a South African study, a cohort
of young women was screened in order to describe links between
their vaginal microbiome and risk of acquiring HIV infection.
The results showed that women with L. crispatus-dominant
microbiota had a 4-fold lower risk of infection than women
with highly diverse bacterial communities (43). Remarkably, not
all Lactobacillus spp. are protective. For example, Lactobacillus
iners increases pro-inflammatory cytokines, predisposing to
infection. This action is implemented by a variety of other taxa,
such as Prevotella melaninogenica, Prevotella bivia, Veillonella,
Mycoplasma, and Sneathia sanguinegens, increasing the HIV
acquisition rate (44, 45). A Lactobacillus-deficient cervicovaginal
district is associated with higher genital pro-inflammatory
cytokine levels and increased genital antigen-presenting cell
activation via lipopolysaccharide (LPS)-sensing pathways and
increased genital CD4+ T cell counts, acting as a “trigger”
of local immunity (3, 43). Conversely, a vaginal ecosystem
with a dominance of lactobacilli, particularly L. crispatus,
is characterized by a low inflammatory microenvironment.
Endocervix and a thick mucous layer represent very important
elements that contribute to innate immune barriers (46). In
the mucous, we can find the presence of IgG, secretory
IgA, lactoferrin, lysozyme, and other antibacterial compounds.
Moreover, T-cells and antigen-presenting cells are also in the
lower reproductive endothelium.
Several studies have reported conflicting findings on the
beneficial activity by Lactobacillusabundance. Higher levels were
found in groups of women with endometrial polyps (EP) or in
women with EP associated with chronic endometriosis (EP +
CE) compared with healthy controls (47).
In contrast, other studies suggested that high levels of
Lactobacillus are significantly associated with increased
reproductive success in women undergoing in vitro fertilization
(IVF) (48).
In recent years, many studies have shown how bacterial
communities can play a key role in fecundation (42, 49).
These new considerations are decisive for the development
of new approaches to improve fertility, conception, healthy
pregnancy, and bacterial colonization of the infant and to
prevent preterm birth. Considering this strong relationship
between microbes and fertility, the main objective must be to
intervene directly on these populations in order to increase
reproductive success outcomes. An example of this strategy is
represented by the application of the probiotics Lactobacillus
brevis CD2, Lactobacillus plantarum FV9, and Lactobacillus
salivarius FV2. These species seem to exercise a protective
action on sperm motility and viability in vitro by preventing
membrane damage induced by reactive oxygen species (35).
This suggests that lactobacilli species resident in the vagina
could be a protective factor for spermatozoa function during
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and after intercourse. This relationship has also been observed
in artificial reproduction technique (ART) outcomes. In fact,
vaginal microbiota composition, on the day of embryo transfer
and after IVF, influenced the success of pregnancy (50). As
described before, some disorders strongly alter cervicovaginal
flora. Uterine microbiota composition has been shown to
be significantly different in women with endometriosis (51).
Furthermore, Cicinelli et al. reported that endometriosis patients
treated with antibiotics before implantation had significantly
better reproductive outcomes compared with those not treated
(52). Endometriosis patients are characterized by low levels
of Lactobacillus spp. and an increase of Streptococcus spp.,
Staphylococcus spp., and Gram-negative bacteria belonging to
the family Enterobacteriaceae. This relationship between bacteria,
endometriosis and reproductive outcomes has been studied,
demonstrating how a “Lactobacillus dominant (LD)” population
and a “non-Lactobacillus dominant” (NLD) show significant
differences in terms of successful outcomes. Specifically, women
with an LD uterine microbiome had markedly higher rates of
implantation [60.7 vs. 23.1% (P = 0.02)], pregnancy [70.6 vs.
33.3% (P = 0.03)], ongoing pregnancy [58.8 vs. 13.3% (P =
0.02)], and live births [58.8 vs. 6.7% (P = 0.002)] compared
with those with an NLD uterine microbiome composition (53).
Furthermore, researchers are studying the functional impact
of uterine microbial population and their relationship with
the microenvironment. The promotion of vaginal health is
influenced by probiotics with various combinations of L. reuteri
L. acidophilus, L. gasseri, L. rhamnosus, L. plantarum, and
L. crispatus. When given as a short course (3–10 days), after
1 month, rates of vaginal colonization by probiotic strains
ranged from 10% for oral L. rhamnosus to 53% for a vaginal
product, including L. gasseri, L. fermentum, L. rhamnosus, and
Pediococcus acidilactici. Treatment with a vaginal L. crispatus
product established persistent colonization up to 1 month in
44%−59% of women (46). However, 1 week after the treatment,
the rates of colonization decreased in sexually active women and
in women yet colonized by endogenous lactobacilli (54). Another
potential approach to modulate cervicovaginal microbiota is
hormone therapy. In 2013, van de Wijert et al. (55) observed
that combined oral contraceptives and progestin-only injectable
contraceptives were mainly associated with a lower incidence
of bacterial vaginosis (BV). In post-menopausal women, when
the concentration of Lactobacilli was reduced, it was observed
that treatment with oral estradiol hormone replacement therapy
seemed to influence vaginal microbiota, increasing colonization
by Lactobacillus spp. (56).
PROSPECTIVE FMT TREATMENT OF
FEMALE GENITAL TRACT DISEASES
The role of commensal bacteria in stimulating local and
systemic immunity appears to be established. Some of the
new strategies for the treatment of diseases are focused on
chemically synthetized molecules or recombinant proteins (57),
and this type of approach requires oral or topical administration.
Moreover, such compounds frequently show low levels of
stability and, sometimes, in cases of recombinant proteins,
contain remnants of inflammatory contaminants (58). Bacterial
strains resident in the gut and vagina crosstalk, which leads
to local and systemic immune regulation. In this regard,
particular bacterial species can be engineered and used as
oral vectors capable of triggering local and systemic immune
responses in order to prevent (e.g., vaccines) or alleviate disease
symptoms (59).
Induction of humoral and cellular immune responses
represents a fundamental aspect involved in preventing female
genital tract disorders. As other secretions, vaginal and cervical
fluid contain mainly IgA and a certain proportion of IgG of
plasma origin (60). The female genital tract does not contain
organized lymphoepithelial structures analogous to intestinal
Peyer’s patches. This aspect is crucial to identify alternative
routes of immunization to bypass local application of antigens.
Thus, oral, rectal and nasal administrations were suggested (61).
Furthermore, a central aspect is represented by the homing
of activated lymphocytes, which depends on the expression of
specific surface receptors that recognize elements on endothelial
cell walls. An example is α4β7 and L-selectin receptor, which
guide immune cells to the gut mucosa and peripheral lymph
nodes, respectively (62). An intriguing study was conducted in
2001 by Kutteh et al. They explored the efficacy of intestinal
tract immunization in the induction of specific antibodies in
human female genital tract secretions. A live attenuated strain
of Salmonella typhi Ty 21a was used as a vector. In this study,
15 women were vaccinated orally, and 11 volunteers received the
same dose rectally. To evaluate the effect on mucosal responses,
seven women that had been vaccinated orally 6 months prior
received a rectal boost. The data showed significant increases
of IgA, predominantly, and IgG in vaginal and cervical fluids.
Increased immunoglobulin levels were also observed after rectal
boosting. This demonstrated that specific antibodies in the female
genital tract induced by primary vaccination could be enhanced
via subsequent rectal administration (60). Two aspects clearly
emerged from this study: (1) the administration of live bacterial
vectors induces a local and systemic immune response; (2) rectal
administration may also induce stimulation at the cervicovaginal
level. In this regard, FMT could be a natural alternative to
recombinant bacterial vectors. In fact, with single or multiple
infusions, large amounts of bacteria and metabolites could be
administered, each of which could serve as an inducer of local
and systemic immune responses.
Indeed, understanding the connection between intestinal and
vaginal microbiota may represent a goal for new treatments of
female genital tract disorders. New gene sequencing techniques
have allowed characterization of the intestinal and vaginal
populations and therefore led to hypotheses of interactions in
states of health or disease. In 2017, Lindheim et al. investigated
stool microbiome of women with polycystic ovary syndrome
(PCOS) and healthy controls. PCOS is a common disorder
affecting 5–10% of women in their reproductive years. As far
as we know, this syndrome is characterized by the presence of
three main features: hyperandrogenism, oligo/anovulation, and
polycystic ovaries on pelvic ultrasound (63). The etiology and
pathogenesis of PCOS remain unclear andmay bemulti-factorial,
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involving genetic, neuroendocrine, and metabolic causes (64).
Other parameters, such as gut barrier integrity, endotoxaemia
and inflammation, were also evaluated. The stool microbiome
of PCOS patients showed a lower diversity and an altered
phylogenetic composition compared to controls. Significant
differences in taxa, with a relative abundance >1%, were not
observed (65). Regarding rare taxa, the relative abundance
of bacteria from the phylum Tenericutes (relevant genera
include Mycoplasma spp., Ureaplasma spp.) and the family S24-
7 (phylum Bacteroidetes) was significantly lower. Moreover,
patients did not show alterations in all markers of gut barrier
function and endotoxaemia (65). These findings suggest that
changes of gut microbiota also had trends similar to the
variations of metabolic symptoms. Other studies observed that
some Gram-negative bacteria belonging to the genera Bacteroides
and Escherichia/Shigella significantly increased in the gut of
PCOS women with obesity. In these conditions, LPS produced
by these microorganisms was demonstrated to induce chronic
inflammation, obesity, and insulin resistance in LPS-infusedmice
(5). In this status, spore-forming species, such as Clostridiales,
decrease, while Proteobacteria and Bacteroidetes increase. Other
evidence suggests a multifactorial relationship in determining
the shape of cervicovaginal microbiota. Recently, a potential
relationship between sex hormones and gut microbiota emerged.
This novel concept has been defined as “microgenderome” (66).
At the time of puberty, sex hormone levels exercise specific
influences on the composition of the microbiota. Removal of gut
microbiota showed an increase in testosterone concentration in
female mice but a decrease in male mice. Thus, the commensal
gut microbiota also had effects on production of the male
sex hormone (67). It is interesting to explore the role of gut
microbiota in PCOS, in which androgen levels in PCOS women
are always elevated. Tremellen and Pearce suggest that dysbiosis
of the gut microbiota (DOGMA) brought about by a high fat-
sugar diet in PCOS patients leads to an increase in intestinal
permeability. Lipopolysaccharide produced by Gram-negative
bacteria traverse the gut wall to enter the circulation, leading
to a chronic state of low-grade inflammation. Activation of
the immune system interferes with insulin receptor, driving
up insulin levels, which boost testosterone production in the
ovary, leading to PCOS. DOGMA theory can account for the
role of gut microbiota in the pathogenesis of PCOS (68). This
evidence has been reinforced by a study on induced PCOS using
a rat model (67), in which the results showed that PCOS rats
displayed abnormal oestrous cycles, represented by increasing
androgen biosynthesis, and exhibited multiple large cysts with
diminished granulosa layers in ovarian tissues. Moreover, the
composition of gut microbiota in rats treated with letrozole, a
non-steroidal aromatase inhibitor, was different from controls.
Lactobacillus, Ruminococcus, and Clostridium species were lower,
while Prevotella species was higher in PCOS rats compared with
control rats. The rats were treated using FMT from healthy
rats. It was found that the oestrous cycles were improved in all
rats in the FMT group, with decreased androgen biosynthesis
and normalized ovarian morphologies. The composition of the
restored gut microbiota in the FMT group was characterized
by an increase in Lactobacillus and Clostridium and a decrease
in Prevotella. This evidence indicated that the dysbiosis of
gut microbiota was associated with the pathogenesis of PCOS
and emphasized the hypothesis aimed at implementing the use
of FMT for extra-intestinal disorders. In fact, there is strong
evidence that host-microbial interactions play a key role in
reproductive health outcomes. The challenge is to find tools and
strategies capable of modulating microbial populations in the
cervicovaginal microenvironment, using probiotics, as well (46).
Other female tract disorders are associated with gut microbiota
alterations, such as endometriosis and BV.
Endometriosis is a condition defined by the presence of
endometriotic gland and stroma outside of the uterine cavity,
ranging in severity levels from I to IV (69). Many studies have
emphasized how immunologic alterations and microbiological
factors, independently or in association with epigenetic changes,
might play a role in the development of the disease (70). Dysbiosis
influences estrogen levels in the circulation (71), and increased
estrogen levels can stimulate growth of ectopic endometriotic
foci and inflammatory activity. Thus, gut microbiota influencing
the regulation of the estrogen cycle could be associated with
endometriosis. In an interesting recent study, Ata et al.
performed an in depth characterization and comparison of
vaginal, cervical, and gut microbiota in women with stage III–
IV endometriosis and healthy controls. The results showed
overall comparable compositions of the vaginal, cervical, and
gut microbiota. However, there were some differences between
the bacterial groups, with some interesting decreases, absences
or increases of some species. Specifically, the complete absence
of Atopobium in the vagina and cervix, together with the
increased abundance of Gardnerella, Escherichia/Shigella, and
Ureoplasma in the cervical microbiome of patients with
endometriosis could be a relevant finding (72). Atopobium
spp. was recently implicated as a gynecological pathogen
associated with bacterial vaginosis, obstetric bacteraemia, and,
possibly, with endometrial cancer (73). These findings suggest
an active role played by resident bacteria in the cervix-
vaginal district and interactions with intestinal microbes. This
bacterial network appears to be related to local and system
female conditions.
As previously mentioned, menstruation and menopause,
caused by hormonal changes, contribute to a drastic modification
in the vaginal microbiota, specifically decreases in lactobacilli.
In this condition, infections by Gardnerella vaginalis (GV)
and Candida albicans are promoted (74). GV plays a key
role in vaginal immunity. In fact, this bacteria is able to
increase levels of several inflammatory factors, such as NF-
kB, TNF-α, myeloperoxidase activity, COX-2, and iNOS. This
pattern of molecules leads to BV (75, 76). Some studies
have shown how the oral administration of probiotics can
influence immunity in the vagina (77). Probiotics are a valid
alternative to antibiotic treatment in order to avoid antimicrobial
resistance. Data suggest that strains of L. acidophilus, L.
rhamnosus and L. johnsonii mitigate GV-vaginosis in mice
(78). Kim et al. have demonstrated that administration of
NK3 (L. plantarum), NK49 (B. longum), and their mixture
alleviated GV-induced BV in mice by reducing TNF-α levels
and myeloperoxidase activity and increasing IL-10 expression.
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This treatment also contributed to COX-2, iNOS and NF-Kb
suppression (77). In this study, the authors also investigated
fecal microbiota composition in mice with GV-induced BV
using qPCR. High levels of GV significantly increased Firmicutes
and Proteobacteria, the main LPS-producers, and suppressed
Bacteroidetes populations in the vagina. Moreover, GV infection
was able to increase inflammatory molecules, such as TNF-α,
NF-Kb, and myeloperoxidase, in the colon. However, treatment
with NK3 and/or NK49 significantly decreased Proteobacteria
and increased Bacteroidetes, contributing to the inhibition of gut
microbiota LPS production (Figure 2). Crosstalk between the gut
and vagina environment seems evident. Oral administration of
probiotics, and then bacteria, might play a crucial role in the
suppression of the pro-inflammatory cytokine expression in the
vagina. This action influences the inflammatory status in the
gut, acting on bacteria and immune cells, such as macrophages,
dendritic cells and local lymphocytes. It could be interesting
to hypothesize a similar action using FMT, which would allow
a direct administration of bacteria and metabolites in the gut,
bypassing stomach passage.
CONCLUDING REMARKS
Undoubtedly, the countless microbial communities present
on the body’s surface and in internal organs are directly
involved in homeostasis (2). Knowledge into the interactions
between the intestinal microbiota and health/disease balance,
due to immune-related actions that influence extra-intestinal
sites and diseases, is deepening. Concerning vaginal districts,
evidence indicates that the immune system is involved in local
disorders (59). Indeed, this relationship could be compellingly
linked to gut microbes. On the other hand, vaginal microbiota
represents a complex biological niche, contributing to the
local health and coinciding with the anatomical intricacy
of the female genital tract. Its proximity and connection
to the intestine allows for strong interactions between gut
and vaginal bacteria. These aspects must also consider the
numerous chemical changes that the female reproductive tract
undergoes with age and, periodically, with hormonal interactions
(35). Then, a refined equilibrium between gut microbiota,
immunity, vaginal microbiota, and hormones is essential in
the physiological state of the female genital tract. Considering
recent literature evidences, a direct action exerted by oral
probiotics in the modulation of vaginal disorders such as
BV appears clear (78). Another important finding was the
association of specific patterns of intestinal bacteria with vaginal
pathologies such as endometriosis and PCOS (67, 72). Alongside
the synergistic action of intestinal and vaginal bacteria, the
hormones, such as oestrogens, influence the cervicovaginal
microenvironment (66). It is necessary to continue focusing
FIGURE 2 | Gut-Vagina cross-talking. Bacteria and immunity cells in vagina and gut are in close communication. Hormonal changes during menopause,
menstruations lead to an overgrowth of anaerobic species such as Gardnerella vaginalis (GV). Bacterial vaginosis (BV), caused by GV, increases an immunity
molecules release which exerts pro-inflammatory effects in situ and in the gut. Proteobacteria overgrowth leads to LPS iper-production establishing an inflammatory
status. Oral probiotics alleviate BV in women. FMT might play a similar role in regulating both altered gut flora and vagina inflammation (74, 77).
Frontiers in Immunology | www.frontiersin.org 7 November 2019 | Volume 10 | Article 2653
Quaranta et al. FMT and Female Reproductive Tract
on the dynamics of these interactions and on the effects on
health status or diseases. The new tools developed in modern
microbiology, such as metagenomic and culturomic analysis,
must lead to a greater understanding of microorganism-host
interactions and modify the simple concept of “commensal”
or “pathogen” (8). The right way is to enhance the biological
context in which the bacterial species live and the biological
pathways they control. Gut bacteria are an “orchestra” exerting
mechanisms of regulation on extra-intestinal bacteria, circulating
hormone levels, and immunity. Indeed, manipulating the
microbiome composition is a potential strategy to prevent
or mitigate several diseases. The next step for the scientific
community must be to clarify what is “normal” in the human
microbiome, including cervicovaginal microbes, in order to
define dysbiotic, disease-associated profiles, with the aim of
providing therapies, or lifestyle interventions to return it to
normal again.
A concrete future prospect could involve “driving” the
bacterial populations that inhabit these organs through
therapeutic procedures, such as fecal transplantation, as yet
demonstrated in CDI resolution (7). FMT consists of a liquid
feces suspension, infused into a recipient colon-site. In this
way, bacteria and metabolites are able to modulate both local
microbial community and systemic immunity, influencing other
districts balances, as hopefully the female genital-tract one. An
advanced, intriguing possibility could involve the infusion of a
synthetic bacterial suspension consisting exclusively of selected
and controlled bacterial populations in order to obtain an “ad
personam” therapeutic approach.
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